Radiopharmaceuticals Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Radiopharmaceuticals Market is projected to expand from USD 6.12 billion in 2025 to USD 8.32 billion by 2031, reflecting a compound annual growth rate of 5.25%. These medicinal formulations, which combine radioactive isotopes with pharmaceutical agents, are essential for both diagnostic imaging and targeted therapeutic interventions. Growth is largely driven by the rising global incidence of chronic diseases, particularly oncology and cardiovascular disorders, which demand high-precision diagnostic tools. Additionally, the aging global demographics sustain demand for nuclear medicine, as elderly populations typically require more frequent monitoring and intervention. According to the World Nuclear Association, more than 50 million nuclear medicine procedures are conducted annually worldwide as of 2025, highlighting the vital role these products play in modern healthcare systems.

Despite this growth, the market encounters significant hurdles related to the complex logistics needed for distribution. The rapid radioactive decay of many clinically vital isotopes necessitates a strictly timed supply chain, where even minor transportation delays can lead to product expiration and wastage. This logistical fragility is intensified by a dependence on a limited number of nuclear reactors for isotope production, creating severe supply vulnerabilities and restricting the availability of these essential treatments in emerging markets.

Market Drivers

The accelerating adoption of targeted radionuclide therapy is fundamentally transforming the global market, moving the industry's focus from diagnostic imaging toward precision therapeutic interventions. Unlike conventional external beam radiation, these systemic treatments employ specific biomarkers to deliver radioactive payloads directly to cancer cells, maximizing efficacy while sparing healthy tissue. The commercial potential of this modality is demonstrated by the robust revenue growth of approved agents. According to BioSpace in October 2024, the prostate cancer therapy Pluvicto generated $386 million in sales during the third quarter alone, marking a 50% year-over-year increase. This adoption underscores the clinical value of theranostics and confirms the shift toward personalized nuclear medicine in oncology.

Concurrently, increased government funding and private investment in nuclear medicine are addressing historical supply chain limitations and driving innovation. Major pharmaceutical companies are actively acquiring specialized biotechnology firms to secure proprietary radioisotope manufacturing capabilities and broaden their oncology portfolios. For instance, Pharmaceutical Technology reported in February 2024 that Bristol Myers Squibb acquired RayzeBio for approximately $4.1 billion to access its actinium-based radiopharmaceutical platform. This trend of strategic consolidation is further solidifying the sector's long-term financial stability; as noted by AstraZeneca in 2024, the company completed its acquisition of Fusion Pharmaceuticals for roughly $2.4 billion, reinforcing the industry's dedication to scaling next-generation radioconjugates.

Market Challenges

The Global Radiopharmaceuticals Market encounters a significant barrier to growth stemming from the complex logistics of product distribution and the inherent instability of its supply chain. Because radiopharmaceuticals contain isotopes with short half-lives, they decay quickly and cannot be stockpiled, requiring a strictly synchronized "just-in-time" delivery model. This constraint implies that even minor delays in transportation inevitably result in product expiration and financial loss, directly reducing the number of patients treated and curbing revenue potential. As a result, healthcare facilities in regions with underdeveloped logistical infrastructure often struggle to access these critical diagnostics and therapies, effectively limiting the market's geographical reach.

This fragility is further compounded by the market's heavy dependence on a small number of nuclear reactors, where a single operational disruption can precipitate a global crisis. According to Nuclear Medicine Europe, in 2024, unexpected delays in the restart of a major production reactor led to supply shortages of critical medical isotopes ranging from 50% to 100% across various regions. Such severe interruptions compel hospitals to cancel or postpone procedures, undermining confidence in nuclear medicine and hindering the overall progress of the industry.

Market Trends

The commercialization of novel radioisotopes is expanding diagnostic capabilities, shifting beyond legacy agents like Gallium-68 to next-generation options such as Copper-64, which offer superior imaging characteristics and logistical benefits. These novel isotopes possess extended half-lives that support centralized manufacturing and wider geographic distribution, effectively mitigating the supply chain constraints associated with shorter-lived tracers. Highlighting the economic potential of these advanced diagnostics, Clarity Pharmaceuticals noted in January 2025 that the current market for first-generation diagnostic PSMA PET imaging is valued at approximately $2 billion in the U.S. alone, positioning copper-based alternatives to capture significant market share by enhancing clinical scheduling flexibility.

Simultaneously, the development of Fibroblast Activation Protein (FAP) inhibitors is establishing a new paradigm in oncology by targeting the tumor microenvironment rather than malignant cells directly. This mechanism enables pan-cancer imaging and treatment of various epithelial tumors, addressing the limitations of antigen-specific radioligands that are often restricted to single indications. Validating the industry's commitment to scaling this promising modality, Contract Pharma reported in May 2025 that Ratio Therapeutics announced an agreement to construct a 65,000-square-foot facility in Utah dedicated to the vertical integration and commercial production of its FAP-targeted pipeline. This investment in infrastructure underscores the rapid transition of FAP inhibitors from experimental research to scalable clinical solutions.

Key Players Profiled in the Radiopharmaceuticals Market

• PharmaLogic Holdings LLC
• Jubilant Radiopharma
• China Isotope & Radiation Corporation
• Siemens Healthineers AG
• SHINE Technologies, LLC
• Ion Beam Applications SA
• Global Medical Solutions
• BWX Technologies. Inc.
• CoquI Radio Pharmaceuticals Corp.
• Evergreen Theragnostics, Inc.

Report Scope

In this report, the Global Radiopharmaceuticals Market has been segmented into the following categories:

Radiopharmaceuticals Market, by Type:

• Diagnostic Radiopharmaceuticals
• Therapeutic Radiopharmaceuticals

Radiopharmaceuticals Market, by Source:

• Nuclear Reactors
• Cyclotrons

Radiopharmaceuticals Market, by End user:

• Hospitals & Clinics
• Diagnostics imaging centre
• Others

Radiopharmaceuticals Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Radiopharmaceuticals Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.